Medicare launches obesity drug coverage, opening new market for Novo Nordisk and Eli Lilly

Traders Union
All News
Financial News
Medicare obesity drug coverage

Highlights

Medicare's Bridge demonstration program starts July 1, enabling eligible seniors to access GLP-1 obesity drugs for a $50 monthly copay.
Novo Nordisk and Eli Lilly estimate 15 million to 20 million Medicare beneficiaries could qualify, but rollout faces administrative hurdles and clinic capacity issues.
The Bridge program's coverage is temporary, ending in 2027, and permanent policy remains uncertain, risking future access for patients starting treatment now.

Bridge program expands access from July 1

As first reported by CNBC, Medicare begins offering obesity drug coverage through its new Bridge demonstration program on Wednesday, allowing eligible seniors to obtain GLP-1 treatments for a $50 monthly copay.

Medicare Part D already covers some GLP-1 medicines for conditions such as diabetes and cardiovascular disease, but federal law has barred coverage when obesity is the sole condition being treated. The Bridge program works around that restriction on a temporary basis and also includes some beneficiaries who are overweight and have related conditions such as prediabetes or uncontrolled hypertension.

Chris Klomp, director of Medicare and deputy administrator of the Centers for Medicare and Medicaid Services, said at the Aspen Ideas Festival last week that several million beneficiaries are expected to use the program. Novo Nordisk and Eli Lilly estimate that roughly 15 million to 20 million older adults in Medicare could qualify for weight loss drugs.

Rollout hurdles and policy uncertainty remain

Doctors say the early rollout may face operational challenges because providers must file prior authorization requests showing that patients meet eligibility standards. Some physicians also warn that stronger demand could put pressure on already busy clinics and pharmacies, while limited public awareness may slow initial uptake.

The longer-term outlook for coverage also remains uncertain because the demonstration program is scheduled to end in 2027. Permanent coverage would require either a change in federal law or support from private insurers offering Part D plans, raising the risk that patients who begin what many experts consider long-term therapy could later lose access.

Juliette Cubanski, director of the Program on Medicare Policy at KFF, said the launch is positive for patients but the temporary nature of the program leaves unanswered what happens after its 18-month duration. That uncertainty matters for beneficiaries who may start treatment without clarity on whether coverage continues in another form.

Our earlier article on Novo Nordisk (NVO) highlighted the company’s restructuring plans, including job cuts, alongside a higher dividend proposal and an accelerated share buyback program. We also noted that NVO was holding above key moving averages, with momentum still bullish but some indicators flashing overbought conditions and a higher near-term volatility risk.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.